Myriad Genetics Inc. (MYGN)

[surf1944]

7:05AM Myriad Genetics announces results from a verification study showed the Myriad myPath Melanoma test effectively differentiated malignant melanoma from benign skin lesions (MYGN) 22.77 : Co announced that results from a verification study showed the Myriad myPath Melanoma test effectively differentiated malignant melanoma from benign skin lesions. Co presented these data at the American Society of Dermatopathology Annual Meeting on Oct. 13, 2013. The verification study evaluated a 23-gene panel designed to differentiate malignant melanoma from benign skin lesions. The study analyzed 464 skin biopsy samples including 254 samples representing melanomas from all major subtypes including superficial spreading, lentigo maligna melanoma, acral, nodular and desmoplastic lesions. Using this set of patient samples, the myPath Melanoma test demonstrated high sensitivity of 89% and specificity of 93% at differentiating malignant melanoma from benign skin lesions.